Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2000 1
2001 1
2002 2
2003 2
2004 1
2005 2
2006 1
2007 3
2008 4
2009 2
2010 5
2011 1
2012 1
2013 2
2014 2
2015 4
2016 8
2017 2
2018 2
2019 2
2020 1
2021 7
2022 4
2023 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

57 results

Results by year

Filters applied: . Clear all
Page 1
Showing results for p l allier[Author]
Your search for P L Olliaro[Author] retrieved no results
Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction.
Tardif JC, Kouz S, Waters DD, Bertrand OF, Diaz R, Maggioni AP, Pinto FJ, Ibrahim R, Gamra H, Kiwan GS, Berry C, López-Sendón J, Ostadal P, Koenig W, Angoulvant D, Grégoire JC, Lavoie MA, Dubé MP, Rhainds D, Provencher M, Blondeau L, Orfanos A, L'Allier PL, Guertin MC, Roubille F. Tardif JC, et al. Among authors: l allier pl. N Engl J Med. 2019 Dec 26;381(26):2497-2505. doi: 10.1056/NEJMoa1912388. Epub 2019 Nov 16. N Engl J Med. 2019. PMID: 31733140 Free article. Clinical Trial.
The primary end point occurred in 5.5% of the patients in the colchicine group, as compared with 7.1% of those in the placebo group (hazard ratio, 0.77; 95% confidence interval [CI], 0.61 to 0.96; P = 0.02). The hazard ratios were 0.84 (95% CI, 0.46 to 1.52) for death from …
The primary end point occurred in 5.5% of the patients in the colchicine group, as compared with 7.1% of those in the placebo group (hazard …
Shared genetic pathways contribute to risk of hypertrophic and dilated cardiomyopathies with opposite directions of effect.
Tadros R, Francis C, Xu X, Vermeer AMC, Harper AR, Huurman R, Kelu Bisabu K, Walsh R, Hoorntje ET, Te Rijdt WP, Buchan RJ, van Velzen HG, van Slegtenhorst MA, Vermeulen JM, Offerhaus JA, Bai W, de Marvao A, Lahrouchi N, Beekman L, Karper JC, Veldink JH, Kayvanpour E, Pantazis A, Baksi AJ, Whiffin N, Mazzarotto F, Sloane G, Suzuki H, Schneider-Luftman D, Elliott P, Richard P, Ader F, Villard E, Lichtner P, Meitinger T, Tanck MWT, van Tintelen JP, Thain A, McCarty D, Hegele RA, Roberts JD, Amyot J, Dubé MP, Cadrin-Tourigny J, Giraldeau G, L'Allier PL, Garceau P, Tardif JC, Boekholdt SM, Lumbers RT, Asselbergs FW, Barton PJR, Cook SA, Prasad SK, O'Regan DP, van der Velden J, Verweij KJH, Talajic M, Lettre G, Pinto YM, Meder B, Charron P, de Boer RA, Christiaans I, Michels M, Wilde AAM, Watkins H, Matthews PM, Ware JS, Bezzina CR. Tadros R, et al. Among authors: l allier pl. Nat Genet. 2021 Feb;53(2):128-134. doi: 10.1038/s41588-020-00762-2. Epub 2021 Jan 25. Nat Genet. 2021. PMID: 33495596 Free PMC article.
Low-Dose Colchicine in Patients With Type 2 Diabetes and Recent Myocardial Infarction in the Colchicine Cardiovascular Outcomes Trial (COLCOT).
Roubille F, Bouabdallaoui N, Kouz S, Waters DD, Diaz R, Maggioni AP, Pinto FJ, Grégoire JC, Gamra H, Kiwan GS, Berry C, López-Sendón J, Koenig W, Delorme L, Elbaz M, Coste P, Provencher M, Bassevitch Z, Blondeau L, L'Allier PL, Guertin MC, Tardif JC. Roubille F, et al. Among authors: l allier pl. Diabetes Care. 2024 Mar 1;47(3):467-470. doi: 10.2337/dc23-1825. Diabetes Care. 2024. PMID: 38181203 Clinical Trial.
A primary end point event occurred in 8.7% of patients in the colchicine group and in 13.1% in the placebo group (hazard ratio 0.65; 95% CI 0.44-0.96; P = 0.03). Nausea was reported in 2.7% and 0.8% in the study groups (P = 0.03), and pneumonia occurred in 2.4% and …
A primary end point event occurred in 8.7% of patients in the colchicine group and in 13.1% in the placebo group (hazard ratio 0.65; 95% CI …
Time-to-treatment initiation of colchicine and cardiovascular outcomes after myocardial infarction in the Colchicine Cardiovascular Outcomes Trial (COLCOT).
Bouabdallaoui N, Tardif JC, Waters DD, Pinto FJ, Maggioni AP, Diaz R, Berry C, Koenig W, Lopez-Sendon J, Gamra H, Kiwan GS, Blondeau L, Orfanos A, Ibrahim R, Grégoire JC, Dubé MP, Samuel M, Morel O, Lim P, Bertrand OF, Kouz S, Guertin MC, L'Allier PL, Roubille F. Bouabdallaoui N, et al. Among authors: l allier pl. Eur Heart J. 2020 Nov 7;41(42):4092-4099. doi: 10.1093/eurheartj/ehaa659. Eur Heart J. 2020. PMID: 32860034 Free PMC article. Clinical Trial.
The beneficial effects of early initiation of colchicine were also demonstrated for urgent hospitalization for angina requiring revascularization (HR = 0.35), all coronary revascularization (HR = 0.63), and the composite of cardiovascular death, resuscitated cardiac arrest, MI, o …
The beneficial effects of early initiation of colchicine were also demonstrated for urgent hospitalization for angina requiring revasculariz …
Novel anti-inflammatory therapies for the treatment of atherosclerosis.
Khan R, Spagnoli V, Tardif JC, L'Allier PL. Khan R, et al. Among authors: l allier pl. Atherosclerosis. 2015 Jun;240(2):497-509. doi: 10.1016/j.atherosclerosis.2015.04.783. Epub 2015 Apr 18. Atherosclerosis. 2015. PMID: 25917947 Review.
This review will highlight specific therapies targeting interleukin-1beta (IL-1beta), P-selectin and 5-lipoxygenase (5-LO). It will also aim to examine the anti-inflammatory effects of serpin administration, colchicine and intravenous HDL-directed treatment of CAD. ...
This review will highlight specific therapies targeting interleukin-1beta (IL-1beta), P-selectin and 5-lipoxygenase (5-LO). It will a …
Genetics of symptom remission in outpatients with COVID-19.
Dubé MP, Lemaçon A, Barhdadi A, Lemieux Perreault LP, Oussaïd E, Asselin G, Provost S, Sun M, Sandoval J, Legault MA, Mongrain I, Dubois A, Valois D, Dedelis E, Lousky J, Choi J, Goulet E, Savard C, Chicoine LM, Cossette M, Chabot-Blanchet M, Guertin MC, de Denus S, Bouabdallaoui N, Marchand R, Bassevitch Z, Nozza A, Gaudet D, L'Allier PL, Hussin J, Boivin G, Busseuil D, Tardif JC. Dubé MP, et al. Among authors: l allier pl. Sci Rep. 2021 May 25;11(1):10847. doi: 10.1038/s41598-021-90365-6. Sci Rep. 2021. PMID: 34035401 Free PMC article. Clinical Trial.
We conducted a genome-wide association study of time to remission of COVID-19 symptoms in 1723 outpatients with at least one risk factor for disease severity from the COLCORONA clinical trial. We found a significant association at 5p13.3 (rs1173773; P = 4.94 10(-8)) near t …
We conducted a genome-wide association study of time to remission of COVID-19 symptoms in 1723 outpatients with at least one risk factor for …
Pharmacogenomics of the Efficacy and Safety of Colchicine in COLCOT.
Dubé MP, Legault MA, Lemaçon A, Lemieux Perreault LP, Fouodjio R, Waters DD, Kouz S, Pinto FJ, Maggioni AP, Diaz R, Berry C, Koenig W, Lopez-Sendon J, Gamra H, Kiwan GS, Asselin G, Provost S, Barhdadi A, Sun M, Cossette M, Blondeau L, Mongrain I, Dubois A, Rhainds D, Bouabdallaoui N, Samuel M, de Denus S, L'Allier PL, Guertin MC, Roubille F, Tardif JC. Dubé MP, et al. Among authors: l allier pl. Circ Genom Precis Med. 2021 Apr;14(2):e003183. doi: 10.1161/CIRCGEN.120.003183. Epub 2021 Feb 9. Circ Genom Precis Med. 2021. PMID: 33560138 Free PMC article.
The genome-wide association study for gastrointestinal events was conducted in all 767 patients in the colchicine arm and found 2 significant association signals, one with lead variant rs6916345 (hazard ratio, 1.89 [95% CI, 1.52-2.35], P=7.4110(-9)) in a locus which coloca …
The genome-wide association study for gastrointestinal events was conducted in all 767 patients in the colchicine arm and found 2 significan …
Direct stenting versus pre-dilation in ST-elevation myocardial infarction: a systematic review and meta-analysis.
Azzalini L, Millán X, Ly HQ, L'Allier PL, Jolicoeur EM. Azzalini L, et al. Among authors: l allier pl. J Interv Cardiol. 2015 Apr;28(2):119-31. doi: 10.1111/joic.12190. J Interv Cardiol. 2015. PMID: 25884895 Free article. Review.
DS was associated with lower mortality (OR 0.55; 95%CI: 0.33-0.94; P = 0.03) in NRSs, and overall (OR 0.56; 95%CI: 0.37-0.86; P = 0.008). Mortality was non-significantly reduced in RCTs (OR 0.56; 95%CI: 0.26-1.23; P = 0.15). DS was also associated with lower …
DS was associated with lower mortality (OR 0.55; 95%CI: 0.33-0.94; P = 0.03) in NRSs, and overall (OR 0.56; 95%CI: 0.37-0.86; P …
Septal myectomy in the era of genetic testing.
Chauvette V, Accad AJ, Georges G, Bouhout I, Garceau P, L'Allier P, Bouchard D. Chauvette V, et al. Among authors: l allier p. J Card Surg. 2021 Apr;36(4):1282-1288. doi: 10.1111/jocs.15365. Epub 2021 Feb 5. J Card Surg. 2021. PMID: 33547670
At 10 years, the survival was 97 3% and 100% in patients with a positive and negative genetic test (p = .33), respectively. CONCLUSION: Although our results suggest that the multiple gene mutations present with different characteristics and phenotypes, midterm results of S …
At 10 years, the survival was 97 3% and 100% in patients with a positive and negative genetic test (p = .33), respectively. CONCLUSIO …
Pharmacogenetics-guided dalcetrapib therapy after an acute coronary syndrome: the dal-GenE trial.
Tardif JC, Pfeffer MA, Kouz S, Koenig W, Maggioni AP, McMurray JJV, Mooser V, Waters DD, Grégoire JC, L'Allier PL, Wouter Jukema J, White HD, Heinonen T, Black DM, Laghrissi-Thode F, Levesque S, Guertin MC, Dubé MP; dal-GenE Investigators. Tardif JC, et al. Among authors: l allier pl. Eur Heart J. 2022 Oct 14;43(39):3947-3956. doi: 10.1093/eurheartj/ehac374. Eur Heart J. 2022. PMID: 35856777 Free PMC article. Clinical Trial.
After a median follow-up of 39.9 months, the primary endpoint occurred in 292 (9.5%) of 3071 patients in the dalcetrapib group and 327 (10.6%) of 3076 patients in the placebo group [hazard ratio 0.88; 95% confidence interval (CI) 0.75-1.03; P = 0.12]. The hazard ratios for …
After a median follow-up of 39.9 months, the primary endpoint occurred in 292 (9.5%) of 3071 patients in the dalcetrapib group and 327 (10.6 …
57 results